New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?

Woo, Hyun Young; Yoo, So Young; Heo, Jeong
Expert opinion on pharmacotherapy
2017Jan ; 18 ( 1 ) :35-44.
저자 상세정보
Woo, Hyun Young -
Yoo, So Young -
Heo, Jeong -
ABSTRACT
There have been no therapies available for patients who experience disease progression after sorafenib treatment. Regorafenib inhibits multiple kinases involved in tumor proliferation and neoangiogenesis, which has produced a survival benefit in hepatocellular carcinoma (HCC) after sorafenib failure. Other active candidate agents are c-Met inhibitors and immune checkpoint inhibitors. Areas covered: This paper presents an updated summary of the preclinical and clinical experience with regorafenib, c-Met inhibitors (tivantinib, cabozantinib and tepotinib), and a checkpoint inhibitor (nivolumab, pembrolizumab) in HCC. The reported data were obtained from abstracts of international conferences and journal articles published up to August 2016 and found in a PubMed search. Expert opinion: Based on favorable data from preclinical and clinical trials, regorafenib, c-Met inhibitor, and checkpoint inhibitors are promising agents for HCC after sorafenib failure. However, further efforts to maximize the survival benefit and minimize adverse events of these drugs in the treatment of HCC are still necessary. Additionally, searching for predictors of good responders could allow these new drugs to be applied in personalized treatments of HCC.
Antineoplastic Agents/*therapeutic use; Carcinoma, Hepatocellular/*drug therapy; Humans; Liver Neoplasms/*drug therapy; Neovascularization, Pathologic/drug therapy; Niacinamide/analogs & derivatives/therapeutic use; Phenylurea Compounds/therapeutic use; Proto-Oncogene Proteins c-met/antagonists & inhibitors
MESH
Antineoplastic Agents/*therapeutic use, Carcinoma, Hepatocellular/*drug therapy, Humans, Liver Neoplasms/*drug therapy, Neovascularization, Pathologic/drug therapy, Niacinamide/analogs & derivatives/therapeutic use, Phenylurea Compounds/therapeutic use, Proto-Oncogene Proteins c-met/antagonists & inhibitors
링크

주제코드
주제명(Target field)
연구대상(Population)
연구참여(Sample size)
대상성별(Gender)
질병특성(Condition Category)
연구환경(Setting)
연구설계(Study Design)
연구기간(Period)
중재방법(Intervention Type)
중재명칭(Intervention Name)
키워드(Keyword)
유효성결과(Recomendation)
Regorafenib, c-Met inhibitor, and checkpoint inhibitors are promising agents for HCC after sorafenib failure.
연구비지원(Fund Source)
근거수준평가(Evidence Hierarchy)
출판년도(Year)
참여저자수(Authors)
대표저자
DOI
https://doi.org/10.1080/14656566.2016.1261825
KCD코드
ICD 03
건강보험코드